Yonsei Med J.  2012 Jul;53(4):863-865. 10.3349/ymj.2012.53.4.863.

Oral Muscle Relaxant May Induce Immediate Allergic Reactions

• Hur GY
• Hwang EK
• Moon JY
• Ye YM
• Shim JJ
• Park HS
• Kang KH

• KMID: 1716891
• DOI: http://doi.org/10.3349/ymj.2012.53.4.863

Abstract

Eperisone and afloqualone act by relaxing both skeletal and vascular smooth muscles to improve circulation and suppress pain reflex. These drugs are typically prescribed with non-steroidal anti-inflammatory drugs (NSAIDs) as painkillers. However, there have been no reports on serious adverse reactions to oral muscle relaxants; and this is the first report to describe three allergic reactions caused by eperisone and afloqualone. All three patients had histories of allergic reactions after oral intake of multiple painkillers, including oral muscle relaxants and NSAIDs, for chronic muscle pain. An open-label oral challenge test was performed with each drug to confirm which drugs caused the systemic reactions. All patients experienced the same reactions within one hour after oral intake of eperisone or afloqualone. The severity of these reactions ranged from laryngeal edema to hypotension. To confirm that the systemic reaction was caused by eperisone or afloqualone, skin prick testing and intradermal skin tests were performed with eperisone or afloqualone extract in vivo, and basophil activity tests were performed after stimulation with these drugs in vitro. In one patient with laryngeal edema, the intradermal test with afloqualone extract had a positive result, and CD63 expression levels on basophils increased in a dose-dependent manner by stimulation with afloqualone. We report three allergic reactions caused by oral muscle relaxants that might be mediated by non-immunoglobulin E-mediated responses. Since oral muscle relaxants such as eperisone and afloqualone are commonly prescribed for chronic muscle pain and can induce severe allergic reactions, we should prescribe them carefully.

Keyword

Muscle relaxant; anaphylaxis; oral provocation test; basophil activation

MeSH Terms

Female
Humans
Hypersensitivity/*etiology
Middle Aged
Muscle Relaxants, Central/*adverse effects
Propiophenones/adverse effects
Quinazolines/adverse effects

Figure

• 

  Fig. 1 Neck X-rays taken after oral intake of afloqualone 20 mg, when stridor and hoarseness were present, show supraglottic airway narrowing.

• 

  Fig. 2 Comparison of CD63 (%) levels following stimulation with calcium ionophore A2319 (3 µM; Sigma-Aldrich, St. Louis, MO, USA), anti-human goat IgE antibodies (1:100 vol/vol; KPL, Gaithersburg, MD, USA), and afloqualone (0.005 and 0.25 mg/mL). IgE, immunoglobulin.

Reference

1. Matsunaga M, Uemura Y, Yonemoto Y, Kanai K, Etoh H, Tanaka S, et al. Long-lasting muscle relaxant activity of eperisone hydrochloride after percutaneous administration in rats. Jpn J Pharmacol. 1997. 73:215–220.

2. Ochiai T, Ishida R. Pharmacological studies on 6-amino-2-fluoromethyl-3-(O-tolyl)-4(3H)-quinazolinone (afloqualone), a new centrally acting muscle relaxant. (II) Effects on the spinal reflex potential and the rigidity. Jpn J Pharmacol. 1982. 32:427–438.

3. Inoue S, Bian K, Okamura T, Okunishi H, Toda N. Mechanisms of action of eperisone on isolated dog saphenous arteries and veins. Jpn J Pharmacol. 1989. 50:271–282.

4. Iwase S, Mano T, Saito M, Ishida G. Effect of a centrally-acting muscle relaxant, eperisone hydrochloride, on muscle sympathetic nerve activity in humans. Funct Neurol. 1992. 7:459–470.

5. Choonhakarn C. Non-pigmenting fixed drug eruption: a new case due to eperisone hydrochloride. Br J Dermatol. 2001. 144:1288–1289.

6. Ueno T, Kawana S. [A case of eperisone hydrochloride (myonal)--induced drug eruption leading to erythema and angioedema]. Arerugi. 2007. 56:709–713.

7. Ribi C, Vermeulen C, Hauser C. Anaphylactic reactions to tolperisone (Mydocalm). Swiss Med Wkly. 2003. 133:369–371.

8. Demitsu T, Tomita Y. Fixed drug eruption due to afloqualone: the first reported case. J Dermatol. 1998. 25:136.

9. Webb LM, Lieberman P. Anaphylaxis: a review of 601 cases. Ann Allergy Asthma Immunol. 2006. 97:39–43.